15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $2.9B | $538M | 67.4% | 16.3% | 11.8% | 10.1% | $589M | — | $526M |
| 2024 | $2.5B | $103M | 58.9% | 6.6% | 2.5% | 2.0% | $405M | — | $784M |
| 2023 | $1.6B | $123M | 65.1% | 8.5% | 3.1% | 2.4% | $165M | — | — |
| 2022 | $1.0B | $190M | 74.2% | 22.3% | 10.3% | 9.2% | $104M | — | — |
| 2021 | $958M | $149M | 75.0% | 17.9% | 8.6% | 7.6% | $219M | — | — |
| 2020 | $789M | $102M | 72.4% | 14.1% | 6.8% | 6.1% | $135M | — | — |
| 2019 | $785M | $155M | 77.1% | 21.9% | 11.1% | 10.1% | $101M | — | $195M |
| 2018 | $713M | $156M | 77.6% | 23.7% | 13.2% | 12.0% | $122M | — | $140M |
| 2017 | $636M | $107M | 76.3% | 25.4% | 11.1% | 10.0% | $108M | — | $119M |
| 2016 | $564M | $104M | 76.1% | 27.3% | 12.5% | 11.2% | $107M | — | $67M |
| 2015 | — | $113M | — | — | 15.8% | 13.5% | $73M | — | $58M |
| 2014 | — | $92M | — | — | 15.8% | 13.1% | $54M | — | $82M |
| 2013 | — | $69M | — | — | 14.5% | 12.1% | $70M | — | $90M |
| 2012 | — | $74M | — | — | 19.1% | 16.5% | $52M | — | $212M |
| 2011 | — | $61M | — | — | 21.5% | 18.5% | $54M | — | $143M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $790M | $152M | 69.4% | 23.1% | 3.2% | 2.8% | $177M | — | $508M |
| Mar '26 | $760M | $124M | 69.2% | 19.8% | 2.6% | 2.3% | $163M | — | $561M |
| Dec '25 | $826M | $141M | 68.4% | 20.5% | 3.1% | 2.7% | $202M | — | $526M |
| Sep '25 | $769M | $119M | 67.2% | 17.9% | 2.7% | 2.3% | $214M | — | — |
| Jun '25 | $745M | $203M | 66.6% | 10.2% | 4.7% | 4.1% | $31M | — | — |
| Mar '25 | $598M | $75M | 67.3% | 16.2% | 1.8% | 1.6% | $141M | — | — |
| Dec '24 | $657M | $27M | 59.9% | 9.2% | 0.6% | 0.5% | $193M | — | $784M |
| Sep '24 | $626M | $52M | 56.8% | 7.7% | 1.3% | 1.0% | $162M | — | — |
| Jun '24 | $630M | $32M | 58.7% | 7.9% | 0.8% | 0.6% | $26M | — | — |
| Mar '24 | $607M | -$7M | 60.2% | 1.3% | -0.2% | -0.1% | $24M | — | — |
| Dec '23 | $617M | $15M | 56.9% | 1.6% | 0.4% | 0.3% | $82M | — | — |
| Sep '23 | $384M | $998000 | 64.7% | 0.1% | 0.0% | 0.0% | $29M | — | — |
| Jun '23 | $292M | $58M | 73.8% | 22.7% | 2.9% | 2.6% | $17M | — | — |
| Mar '23 | $277M | $49M | 74.4% | 20.4% | 2.6% | 2.3% | $37M | — | — |
| Dec '22 | $274M | $50M | 74.3% | 19.7% | 2.7% | 2.4% | $46M | — | — |
| Sep '22 | $254M | $47M | 74.2% | 23.5% | 2.7% | 2.4% | $21M | — | — |
| Jun '22 | $264M | $55M | 74.0% | 25.7% | 3.2% | 2.9% | $13M | — | — |
| Mar '22 | $231M | $38M | 74.3% | 20.1% | 2.1% | 1.9% | $25M | — | — |
| Dec '21 | $250M | $15M | 75.3% | 7.3% | 0.9% | 0.8% | $59M | — | — |
| Sep '21 | $230M | $47M | 74.5% | 23.2% | 2.7% | 2.5% | $59M | — | — |
How the market has priced GMED against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Globus Medical Inc's revenue has grown 30.1% per year, and net income grown 39.4% per year. These are computed facts, not advice.
As of FY2025, Globus Medical Inc reported — of total debt against $526M of cash.
In FY2025, gross margin was 67.4%, operating margin 16.3%, and net margin 18.3%.
Globus Medical Inc's P/E (TTM) is 19.92 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the GMED stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 19.8× as of Nov '26) can differ. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.